奥锐特药业股份有限公司2024年向不特定 对象发行可转换公司债券信用评级报告 CSCI Pengyuan Credit Rating Report 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人 员与评级对象不存在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告 遵循了真实、客观、公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的 合法性、真实性、准确性和完整性作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组 织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、 持有任何证券的建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导 致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时， 本评级机构已对受评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变 更信用评级。本评级机构提醒报告使用者应及时登陆本公司网站关注被评证券信用评级的 变化情 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-034 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券网上路演公告 参与方式一：网上路演网站：约调研（https://www.yuediaoyan.com/） 参与方式二：微信扫一扫以下微信小程序二维码： 三、参加人员：发行人管理层主要成员和主承销商相关人员。 敬请广大投资者关注。 特此公告。 发行人：奥锐特药业股份有限公司 保荐人（主承销商）：海通证券股份有限公司 保荐人（主承销商）：海通证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥锐特药业股份有限公司（以下简称"奥锐特"或"发行人"）向不特定对象发行可转换 公司债券（以下简称"本次发行"）已获得中国证券监督管理委员会证监许可〔2024〕924号 文同意注册。 本次发行的可转换公司债券将向发行人原股东优先配售，原股东优先配售后余额部分（含 原股东放弃优先配售部分）采用网上通过上海证券交易所交易系统向社会公众投资者发售的方 式进行。本次发行的可转换公司债券募集说明书摘要和发行公告已刊登 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-033 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券发行公告 保荐人（主承销商）：海通证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次发行基本信息 | 可转债代码 | 111021 | | | | | | 可转债简称 | 奥锐转债 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 原股东配售代码 | 715116 | | | | | | 原股东配售简称 | 奥锐配债 | | | | | | 转债申购代码 | 713116 | | | | | | 转债申购简称 | 奥锐发债 | | | | | | 发行日期及时间 | （2024 | | 年 | 7 | 月 | 26 | 日）（9:30-11:30,13:00-15:00） | | | | | | | 股权登记日 | 2024 | 年 | ...

股票代码：605116 股票简称：奥锐特 奥锐特药业股份有限公司 Aurisco Pharmaceutical Co.,Ltd. （住所：浙江省天台县八都工业园区） 向不特定对象发行可转换公司债券 募集说明书摘要 保荐机构（主承销商） （上海市广东路 689 号） 二〇二四年七月 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券募集说明书摘要 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券募集说明书摘要 重大事项提示 投资者在评价公司本次发行的可转换公司债券时，应特别关注下列重大事 项： 一、公司本次发行的可转换公司债券的信用评级 本次可转换公 ...

奥锐特药业股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 奥锐特药业股份有限公司（以下简称"公司"）第三届监事会第七次会议于 2024 年 7 月 23 日在公司会议室以现场结合通讯方式召开。本次会议的通知于 2024 年 7 月 19 日以邮件结合电话方式送达全体监事及相关人员，会议由监事会 主席金平召集并主持，应到监事 3 人，实到监事 3 人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《奥锐特 药业股份有限公司章程》以及相关法律、法规的有关规定，会议形成的决议合法 有效。 二、监事会会议审议情况 参会监事对相关议案进行了充分讨论，以现场结合通讯方式通过以下议案， 形成决议如下： （一）逐项审议通过《关于进一步明确公司向不特定对象发行可转换公司 债券方案的议案》 证券代码：605116 证券简称：奥锐特 公告编号：2024-032 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、债券利率 本次发行的可转债票面利率设定为：第一 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 28.15 CNY per share [8][9]. Core Insights - The company is transitioning from its predecessor, Dagu Chemical, to an international player, Aurite, focusing on the development and production of complex raw materials and formulations. The company has achieved significant milestones, including the approval of its first formulation product, Dydrogesterone tablets, which began mass production in Q3 2023 [10][14]. - The company has a strong pipeline of new products and is expanding its production capacity, particularly in high-demand areas such as cardiovascular and oncology drugs. The expected net profits for 2024-2026 are projected to be 381 million CNY, 498 million CNY, and 654 million CNY, respectively [10][17]. - The company is actively pursuing an integrated strategy of raw materials and formulations, aiming to enhance its market position and profitability through innovative product offerings and increased production capacity [10][14]. Summary by Sections Company Overview - Aurite specializes in the research, production, and sales of complex raw materials and formulations, with a focus on high-quality pharmaceutical chemicals. The company has been in operation for over 20 years and has established a global sales network [21][126]. Financial Performance - In 2023, the company achieved a revenue of 1.263 billion CNY, a year-on-year increase of 25.24%, and a net profit of 289 million CNY, up 37.19% from the previous year. The earnings per share (EPS) for 2023 was 0.71 CNY [10][142]. Product Development - The company has received regulatory approval for Dydrogesterone tablets, which are expected to significantly contribute to revenue growth. The sales volume for this product in 2023 was approximately 38.34 million tablets, generating revenue of 89.85 million CNY [10][61]. - The company is also advancing its product pipeline in areas such as peptide and oligonucleotide drugs, which are anticipated to become new growth drivers for the company [10][55]. Market Position - Aurite has a competitive advantage in high-end raw materials, with a strong market presence in cardiovascular and oncology products. The company is expected to benefit from increased production capacity and market demand for its products [10][17]. - The company is actively participating in centralized procurement to enhance its market share and profitability [10][14].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 30.00, compared to the last closing price of 25.28 [1][10]. Core Views - The company's Q1 performance exceeded market expectations, with significant growth in both the formulation and peptide businesses. The sales of Dydrogesterone tablets are gradually increasing, contributing to the overall revenue growth [2][10]. - The company is expected to achieve a net profit attributable to shareholders of 1.75 to 2.15 billion yuan for the first half of 2024, representing a year-on-year increase of 82% to 124% [10]. - The report highlights the company's strategic focus on integrating raw materials and formulations, which is anticipated to accelerate the sales of Dydrogesterone tablets [10]. Financial Summary - The company's revenue is projected to grow from 1,263 million yuan in 2023 to 2,559 million yuan by 2026, with a compound annual growth rate (CAGR) of approximately 23.61% [12]. - The net profit attributable to shareholders is expected to increase from 400 million yuan in 2024 to 676 million yuan in 2026, with a net profit growth rate of 30% [12]. - The diluted earnings per share (EPS) is forecasted to rise from 0.71 yuan in 2023 to 1.66 yuan in 2026, indicating strong profitability growth [12].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [10]. Core Views - The report highlights that the volume trend of Dydrogesterone tablets in Q2 2024 exceeds previous expectations. The company's promotional pace and favorable competitive landscape suggest that the growth of its formulation products will be sustainable. Additionally, the release of production capacity for flexible products like Semaglutide is expected to contribute significantly to performance. The EPS forecasts for 2024-2026 have been raised to 0.96, 1.25, and 1.57 yuan respectively, with the closing price on July 10, 2024, corresponding to a PE of 27 times for 2024 [9][12]. Summary by Sections Earnings Forecast and Valuation - The company is expected to achieve a net profit attributable to shareholders of 1.75 to 2.15 billion yuan in H1 2024, representing a year-on-year growth of approximately 82% to 124%. For Q2 alone, the estimated net profit is around 1.13 billion yuan, showing a year-on-year increase of about 126% and a quarter-on-quarter increase of about 37% [12]. Investment Highlights - The growth in H1 2024 is attributed to the steady sales growth of advantageous raw materials and the gradual increase in formulation products. The report anticipates that the commercialization of high-barrier raw materials and formulation products will support sustained high growth in revenue and profit from 2024 to 2026. The company’s technology and product layout in the small nucleic acid and peptide fields are expected to open up long-term growth opportunities [9][12]. Financial Projections - The projected operating revenue for 2024 is 1.666 billion yuan, with a year-on-year growth rate of 31.97%. The net profit attributable to shareholders is projected to be 388 million yuan, with a growth rate of 34.06%. The EPS is expected to reach 0.96 yuan in 2024 [26][27].

业绩持续高增，司美格鲁肽投产在即 [Table_Finance] 公司盈利预测及估值 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 1008.08 1262.53 1720.70 2189.03 2639.97 增长率 yoy% 25.48% 25.24% 36.29% 27.22% 20.60% 净利润（百万元） 210.96 289.42 395.25 515.49 671.75 增长率 yoy% 25.04% 37.19% 36.57% 30.42% 30.31% 每股收益（元） 0.52 0.71 0.97 1.27 1.65 每股现金流量 0.41 0.95 0.35 0.78 1.33 净资产收益率 12.59% 14.71% 17.16% 19.80% 22.42% P/E 48.67 35.48 25.98 19.92 15.29 PEG 1.94 0.95 0.71 0.65 0.50 P/B 6.13 5.22 4.46 3.94 3.43 备注：数据截至 2024.7.9 分析师：祝嘉琦 电话：021-20315150 [Table_Profit] ...

奥锐特药业股份有限公司 重要内容提示： 公司 2024 年半年度归属于上市公司股东的扣除非经常性损益的净利润 预计在 17,361.04 万元至 21,361.04 万元之间，与上年同期（法定披 露数据）相比，将增加约 7,861.22 万元到 11,861.22 万元，同比增加 约 83%到 125%。 2024 年半年度业绩预增公告 本次业绩预告适用情形为：实现盈利，且净利润与上年同期相比上升 50%以上。 一、本期业绩预告情况 （二）业绩预告情况 1 经财务部门初步测算，公司 2024 年半年度实现归属于上市公司股东的净利 润预计在 17,500.00 万元至 21,500.00 万元之间，与上年同期（法定披露数据） 相比，将增加约 7,910.29 万元到 11,910.29 万元，同比增加约 82%到 124%。 公司 2024 年半年度归属于上市公司股东的扣除非经常性损益的净利润预计 在 17,361.04 万元至 21,361.04 万元之间，与上年同期（法定披露数据）相比， 将增加约 7,861.22 万元到 11,861.22 万元，同比增加约 83%到 125%。 （三）本次业绩预告为公司 ...